BioSpace News Archive

Myrtelle Announces Presentation of Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the American Society of Gene and Cell Therapy 26th Annual Meeting.

QSAM Biosciences, Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, and RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the U.S., announced today a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam® (Samarium-153 DOTMP).

SAB Biotherapeutics yesterday reported financial results for the first quarter ended March 31, 2023, and provided a company update.

Biocoat Incorporated announced today that it has added Gregory (Greg) Santorno as the Global Vice President of Sales and Marketing.

Modular Medical, Inc. today announced the pricing of an upsized underwritten public offering of 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common stock.

HTG Molecular Diagnostics, Inc., a platform-based life science tools and drug discovery company, reported achievement of another technical milestone in its drug discovery business.

Viatris Inc. published its 2022 Sustainability Report showcasing its commitment, impact and progress on building sustainable access to medicine as it continues to make a positive difference across key areas including Access and Global Health, Our People, the Environment and the Community.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced the launch of its BravoAAV and ProntoLVV viral vector platforms.

X4 Pharmaceuticals, Inc. today announced that it has agreed to sell an aggregate of 42,784,203 shares of common stock (or pre-funded warrants in lieu thereof) to certain institutional accredited investors in a private investment in public equity (PIPE) financing.

NurExone Biologic Inc. (the “Company” or “NurExone”) (TSXV: NRX) (FSE: J90) (NRX.V) announces that the Company has received an issue notification from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent NO. 11,648,260, granted for the period of 20 years from filing date until March 27, 2039.